Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (460)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04522908 | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH |
| 2 |
| Jan 27, 2025 |
| clinicaltrials |
| NCT04767906 | Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors(CaPture) | completed | Phase 2 | 16 | University of LeipzigOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT00410956 | Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02528643 | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 165 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Dec 6, 2024 | clinicaltrials |
| NCT03009461 | Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis | completed | Phase 2 | 64 | Peking UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04701060 | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | completed | Phase 2 | 25 | NovoCure Ltd.INDUSTRY | 6 | Nov 14, 2024 | clinicaltrials |
| NCT05003700 | Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 39 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04954794 | TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02) | completed | Phase 2 | 29 | Fudan UniversityOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03419897 | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | completed | Phase 2 | 249 | BeiGeneINDUSTRY | 8 | Oct 26, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT04011033 | Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC | completed | Phase 2 | 60 | Beijing YouAn HospitalOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | completed | Phase 2 | 156 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT04170556 | Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)(GOING) | completed | Phase 1 / Phase 2 | 69 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01752933 | SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 52 | Astex Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 27, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT03510871 | Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 43 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04518852 | TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC | completed | Phase 2 | 27 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06232759 | TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 56 | Guangxi Medical UniversityOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT04172571 | A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 31 | AkesoINDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT04842565 | cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria | completed | Phase 2 | 20 | Fudan UniversityOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT05040438 | Natural Killer (NK) Cell Therapy in Locally Advanced HCC | completed | Phase 2 | 17 | Vaxcell Bio, Co., Ltd.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 114 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04444167 | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04728321 | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 32 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2024 | clinicaltrials |
| NCT02273362 | Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02182687 | Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant(SBRTvsTACE) | completed | Phase 2 | 60 | Lahey ClinicOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT03893695 | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | completed | Phase 1 / Phase 2 | 20 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT02695628 | [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer | completed | Phase 2 | 5 | Stanford UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT03535259 | Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma(SIRAHCC) | completed | Phase 2 | 86 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT03230318 | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma(FIDES-01) | completed | Phase 2 | 148 | Basilea PharmaceuticaINDUSTRY | 11 | Dec 19, 2023 | clinicaltrials |
| NCT01624285 | Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | completed | Phase 2 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT02561273 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 54 | University of NebraskaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT05007548 | to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve | completed | Phase 2 | 30 | National Atomic Research Institute, TaiwanOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT00355238 | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer | completed | Phase 2 | 137 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 1, 2023 | clinicaltrials |
| NCT02279719 | A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 97 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02232633 | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | completed | Phase 2 | 45 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT01336933 | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 2 | 34 | University of NebraskaOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04942665 | Low Dose ICG for Biliary Tract and Tumor Imaging(ICG) | completed | Phase 2 | 60 | University of FloridaOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT00539643 | Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma | completed | Phase 2 | 101 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT00095992 | SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer | completed | Phase 2 | 15 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03572582 | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma(IMMUTACE) | completed | Phase 2 | 49 | AIO-Studien-gGmbHOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT03222076 | Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 30, 2025source: clinicaltrials